A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

NCT05084508 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Chickenpox

Interventions

BIOLOGICAL: Investigational varicella vaccine low potency
BIOLOGICAL: Investigational varicella vaccine medium potency
BIOLOGICAL: Investigational varicella vaccine high potency
BIOLOGICAL: Licensed varicella vaccine Lot 1
BIOLOGICAL: Licensed varicella vaccine Lot 2
BIOLOGICAL: Measles, mumps, and rubella vaccine
BIOLOGICAL: Hepatitis A vaccine
BIOLOGICAL: 13-valent pneumococcal conjugate vaccine

Sponsor

GlaxoSmithKline